Canadian investment group TRC Capital—well known for its min-tender offer strategy—has now set its sights on Ionis, and the biotech group is not happy.
Shares in Cerecor leaped after the biotech licensed an antidepressant candidate to Johnson & Johnson, bringing in more cash to advance its pipeline.
The reduction, which amounts to about one-third of NantHealth’s headcount, will lower costs at the Patrick Soon-Shiong-helmed company.
Sarepta CEO Doug Ingram aims to raise $250 million in a public stock offering as the company looks beyond its first product, DMD therapy Exondys 51.
Fresh from the news that its lead pipeline candidate is back under FDA review with a verdict due before year-end, Aeterna has just announced the departure of…
Sarepta offers Exondys 51 outside of the U.S. through a managed access program run by Clinigen, as an EMA decision is expected next year.
With investors clamoring for a deal to broaden its focus, Gilead could do a lot worse than make a bid for Incyte, Leerink analysts say.
Silence Therapeutics has asked the U.K. High Court of Justice to rule on an intellectual property dispute with Alnylam and The Medicines Company.
The delisting plan of Chinese vaccine maker Sinovac has been complicated by a bribery case and a new bid.
The FDA's rejection of Coherus BioSciences' biosimilar version of Amgen's Neulasta means that 51 people at the company will lose their jobs.